GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
M

Maat Pharma MAAT.PA · EUR

Health Care · Euronext Paris · 🇫🇷 France

Compare

1.09

0.00%

Close of 9 Nov 2026, in EUR

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Maat Pharma

Its shares trade on Euronext Paris under the ticker MAAT.PA. It has been listed since 8 November 2021. In the fiscal year to 31 December 2025, it reported revenue of €4.5m and a net loss of €31.1m. At that date it held total assets of €44.6m and shareholders' equity of €1.8m.

Maat Pharma SA operates as a clinical-stage microbiome therapeutics company. The company is headquartered in Lyon, Auvergne-Rhone-Alpes. The company went IPO on 2021-11-08. The firm specializes in the microbiome therapy that is aimed to treatment of Gut Microbiota alteration (Dysbiosis) using patient-specific biotherapeutics in patients with serious medical conditions. Its MaaT Microbiome Restoration Therapy (MMRB) discovery and analysis platform supports the evaluation of drug candidates, the determination of new disease targets and the identification of biomarkers for microbiome-related conditions.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Biotechnology
Listed since
8 Nov 2021
Employees
47

Leadership

Pay as last reported

  • Dr. Jean-Marie LefevreChairman of the Board
  • Mr. Herve AffagardChief Executive Officer, Co-Founder, Director
  • Mr. Eric SoyerChief Financial Officer
  • Ms. Carole SchwintnerChief Technology Officer
  • Dr. Sheri SimmonsActing Chief Scientific Officer
  • Mr. Jonathan ChriquiChief Business Officer
  • Dr. Frederic FasanoChief Strategy and Corporate Development Officer
  • Dr. Behzad Kharabi MasoulehActing Chief Medical Officer
  • Ms. Emilie PlantamuraDeputy Chief Medical Officer
  • Ms. Isabelle De CremouxNon-Executive Director
  • Ms. Muriel PrudentNon-Executive Director
  • Dr. Claude BertrandIndependent Director

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Headquartered in Lyon, France, with a focus on microbiome therapeutics.
  • Specializes in patient-specific biotherapeutics for gut microbiota alteration treatment.
  • Operates a MaaT Microbiome Restoration Therapy platform for drug evaluation.

Weaknesses

  • Limited to 47 full-time employees, indicating a small operational scale.
  • IPO occurred in 2021, suggesting a relatively new public company.
  • Clinical-stage company with no mention of commercialized products.

Opportunities

  • Growing interest in microbiome therapies for serious medical conditions.
  • Potential for expanding MaaT Microbiome Restoration Therapy platform applications.
  • Opportunity to address gut microbiota alteration through patient-specific treatments.

Threats

  • Competition in the biotechnology sector for microbiome therapeutics.
  • Regulatory challenges in developing clinical-stage therapies.
  • Dependence on clinical trial success for future growth.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.